Trial Profile

An Open-label, Crossover Study to Evaluate Rozanolixizumab Self-administration by Study Participants With Generalized Myasthenia Gravis

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 11 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rozanolixizumab (Primary)
Indications Myasthenia gravis
Focus Registrational; Therapeutic Use
Sponsors UCB Biopharma

Most Recent Events

13 May 2025 According to an UCB media release, Data from this study will be presented at the Myasthenia Gravis Foundation of America (MGFA) International Conference taking place May 13-15, 2025, at The Hague, The Netherlands.
03 Apr 2025 According to UCB media release, data from this study will be presented at American Academy of Neurology (AAN) meeting, San Diego California, April 5- 9, 2025.
22 May 2024 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com